Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Doravirine - Merck & Co

Next Previous
X
Search
Drug Profile

Doravirine - Merck & Co

Alternative Names: MK-1439; MK-1439-019; Pifeltro; PIFELTRO

Latest Information Update: 26 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Merck & Co; National Institute of Allergy and Infectious Diseases
  • Class Antiretrovirals; Benzonitrile; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Pyridones; Small molecules; Triazoles
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - HIV-1 infections
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed HIV-1 infections

Most Recent Events

  • 06 Mar 2023 Merck Sharp & Dohme LLC completed a phase III trial in HIV-1 infections (Combination therapy, Treatment-naive) in Austria, Denmark, Germany, Italy, Portugal, Romania, Spain, United Kingdom (PO) (NCT02275780) (EudraCT2014-001127-69)
  • 11 May 2022 Preregistration for HIV-1 infections (In children, In adults, In the elderly) in European Union (PO) (Merck pipeline, May 2022)
  • 11 May 2022 Preregistration for HIV-1 infections (In children, In adults, In the elderly) in USA (PO) (Merck pipeline, May 2022)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top